DiaKine Therapeutics Inc.
This article was originally published in Start Up
DiaKine Therapeutics. is a biopharmaceutical company focused on novel treatments for type 1 and type 2 diabetes. The company is developing a molecule called lisofylline and related analogs to modulate the inflammatory response that triggers the destruction of insulin-producing beta cells in the pancreas.
You may also be interested in...
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.
The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. Pharma firms must identify products that will benefit from innovative pricing models, and then forge the types of collaborations that will support those models.